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Introduction 
Magnetic resonance imaging (MRI) is a medically important test that provides 
a painless, noninvasive way to visualize images of the body by using a strong 
magnetic field. The machine quickly changes the direction of the magnetic field in 
certain increments and measures the time it takes for protons to change their 
direction, lining up with the magnetic field again. The time taken for the protons to 
realign is called the overall relaxivity rate (Rl). Abnormalities, especially tumors, are 
expressed in MRI images because their relaxivity rates are quite different from the 
relaxivity rates of normal tissues. 
To help enhance MRI images, several contrast agents have been developed in 
the past that can be injected into the patient's bloodstream. The contrast agents 
studied and synthesized in this research contain a metal called gadolinium. Contrast 
agents containing gadolinium can be excreted in the urine by glomerular filtration, 
which is a key characteristic of most contrast agents in general. In the last few 
decades, the use of contrast agents has drastically increased due to their 
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enhancement and increased specificity. The most common contrast agents currently 
used include Magnevist, ProHance, and Omniscan. 
For the contrast agent to be useful and effective, it must have several key 
characteristics. First, it must have an adequate amount of tissue specificity. When 
injected into the patient, it should go to one area of the body in a higher 
concentration than anywhere else. The agent must also stay there long enough to 
allow for image enhancement. Second, the contrast agent must have a long shelf 
life. If the material isn't stable, not only is it unsafe to use, it won't be available for 
long-term use. A contrast agent should have a shelf life of years, not months or 
days. Third, as mentioned before, the body must be able to completely remove the 
contrast agent from the targeted area or organ. While most contrast agents are 
excreted in the urine, it must also have low toxicity as to prevent harming the 
patient. Lastly, to minimize dosage, the contrast agent must be able to alter the 
image intensity at a low concentration. This helps keep the dosage at a minimum 
while still producing enhanced images (Contrast Media 454}. 
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In this research several different synthesis reactions were completed and 
tested for accuracy, using NMR and thin-layer chromatography (TLC). The results 
ensured that the desired product was produced before proceeding with the next 
reaction. This thesis describes the synthesis, purification, characterization, and testing 
of a novel contrast agent, comparing it to current contrast agents being used today. 
The final product was tested using Tl relaxation rates to compare the newly 
developed agent, which was synthesized using a piperazine-methoxyphenyl group, 
to those contrast agents in use today. 
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Background 
While magnetic resonance imaging was first used in the 1970s, it was not 
apparent that contrast agents would be helpful in visualizing MRI images until the 
1980s. It was discovered that running MRI with contrast agents significantly 
improved the visualization and specificity of images obtained. Experimenters focused 
specifically on contrast agents containing gadolinium because they have the highest 
paramagnetic effect, meaning they enhance the Tl relaxivity rate the most. 
The main parameter that determines signal intensity and contrast agent 
enhancement is the term relaxivity. The two types of relaxivity rates are termed Tl 
and T2. The Tl relaxation rate depends on longitudinal relaxation of protons. T2 
relaxation is known as transverse relaxation and measures the time taken for the 
protons to lose coherency (Preston 2006). This research focused on overall Tl 




A contrast agent that primarily focuses on the Tl relaxivity rate is called a 
positive relaxation agent because when the Tl relaxivity rate is decreased, a higher 
intensity and enhancement of the image results (Contrast Media, 455). 
In contrast agents, paramagnetic ions such as Gd3+ are used the most 
frequently because they have the highest number of unpaired electrons and the 
highest susceptibility to being magnetized when placed under a magnetic field 
(Contrast Media, 455). Of the four categories of magnetic susceptibility, 
paramagnetic ions give the most enhanced images. Diamagnetic, super-
paramagnetic, and ferromagnetic ions don't show as much contrast in MRI images, 
so they are of little to no interest as contrast agents. In addition, paramagnetic ions 
have shown the greatest flexibility in design and structure when being used as 
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contrast agents, so the most attention has been given to paramagnetic agents such 
as gadolinium, lanthanum, and terbium. Lanthanum and terbium are weakly 
paramagnetic, where gadolinium is highly paramagnetic. Therefore, because 
gadolinium is more highly susceptible in a magnetic field! it gives more enhanced 
Tl-weighted images and is used more often. Gadolinium has seven unpaired 
electrons! giving a high affinity to the chelate. The ion also has a long relaxation 
time, is completely excreted by the kidneys, and has been proven to give the most 
enhanced images. Because gadolinium chelates are the main class of contrast agents 
currently being used, this research was limited to examining Tl-weighted 
paramagnetic contrast agents containing gadolinium. 
Along with a paramagnetic compound's ability to become magnetized when 
being placed under a magnetic field, another important factor to consider is its 
ability to become demagnetized upon removal. The act of paramagnetic particles 
losing their magnetization and returning to random orientations between pulses is 
crucial for MRI imaging- every time the magnetic field pulses and changes directions 
in specified increments! the particles return to random orientations between each 
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pulse. This is what the overall Tl relaxivity rate measures- the amount of time it 
takes for water protons in the body to realign to the pulsing magnetic field after 
being in random orientation (Contrast Media, 455). 
When studying or synthesizing contrast agents, another important factor to 
be considered is the osmolality of the compound. Injections burn or sting if their 
osmolalities differ significantly from the osmolality of blood, so companies that 
produce contrast agents want the contrast agent osmolalities to be as close as 
possible to the blood osmolality. According to the U.S. National Library of Medicine/ 
the average blood osmolality is 275-295 mOsmol/kg (milliosmoles per kilogram). 
Magnevist has approximately 7 times the osmolality of blood plasma with a value of 
1960 mOsmol/kg. ProHance only has 2.2 times more with a value of 630 
mOsmol/kg. Omniscan has an osmolality 2.8 times more than that of blood plasma 
with a value of 798 mOsmol/kg (Contrast Media p. 462-463). 
Most contrast agents are considered to be chelates. Chelates are ligands that 
are bound to a central metal molecule at several different points. The first 
gadolinium contrast agent to be approved as an MRI contrast agent was Magnevist, 
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introduced in 1988. (Contrast Media, 462). In Magnevist, the chelate has a 
gadolinium atom bound to three different nitrogen atoms in the chelate. 
Additionally, the gadolinium (III) ions are bound to three carboxyl groups, which give 
the chelate an overall charge of negative two. Magnevist is a linear molecule and 
has an osmolality of 1960m0smol/kg. Magnevist is excreted exclusively in the urine 
and is shown below in Figure B. 
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ProHance, shown in Figure C, was approved for use in 1992 and was the first 
agent with a cyclic structure to be developed. Because of its cyclical structure, it is 
very stable in vivo. The ligand carries a charge of negative three and the gadolinium 
carries a charge of positive three, giving the molecule a net charge of zero. The 
osmolality of ProHance is 630 mOsmol/kg, which is approximately 2.2 times that of 
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the blood. Because of the lower osmolality, there is approval for dosage up to 
0.3mmol/kg (Contrast Media/ 463). 
Figure C 
Omniscan, shown in Figure D1 was approved for use in 1993 shortly after 
ProHance. Omniscan has a complex structure and is a variant of the linear structure 
of Magnevist. The ligand has a charge of negative three and the gadolinium has a 
charge of zero, but the molecule achieves neutrality at the cost of a large decrease 
in stability. Omniscan's osmolality is 798m0smol/kg, which is 2.8 times the 
osmolality of blood plasma. Because of the complex structure and lack of stability, 
Omniscan is only approved for use in adults. (Contrast Media/ 463). 
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FigureD 
For the contrast agent to be most effective, it must have an adequate amount 
of tissue specificity. When injected into the patient, it should go to one area of the 
body in higher concentration than anywhere else and stay long enough to allow for 
image enhancement. When designing a contrast agent with higher specificity, WAY-
100635, a piperazine drug shown in Figure E, was considered. WAY-100635 is a 
selective 5-HTlA receptor antagonist that shows high selectivity to a range of 
central nervous system receptors including dopamine, gamma-amino butyric acid, 
histamine, and ion receptors. 5-HTlA is a serotonin receptor. When tested in rats, 
WAY-100635 binds to rodent 5-HTlA receptors in the brain. Therefore, it has been 
proven that WAY-100635 has the ability to penetrate the blood-brain barrier. Not 
only can WAY-100635 enter the brain, it has the ability to stay for approximately 30-
13 
90 minutes, which is long enough for MRI images to be taken. High specificity was 
the primary goal for creating a new contrast agent, so the functional group on the 
right side of the molecule was chosen to be synthesized and added to the desired 
contrast agent. 
Figure E 
The side effects to gadolinium-based contrast agents are very rare but can 
include nausea, taste prevention, dizziness, and hives. These symptoms occurred in 
approximately 1% of patients. In previous clinical trials, conclusions were made after 
looking at stability in vivo that ProHance is the safest agent, while Omniscan is the 
least safe (Contrast Media, 462-463). Clinical trials also established that the safest 
and most effective dose to administer is 0.1 mmol/kg, which equates to 0.2 ml/kg. 
Agents with lower osmolalities can be given in higher doses. However, giving 
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amounts below the full dose of O.lmmol/kg caused metastases and other 
abnormalities to be easily missed because of lack of enhancement No gadolinium 
contrast agents are approved for use in children under the age of two years. 
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Methods 
The primary goal was to synthesize a contrast agent that was water-soluble, 
contained gadolinium, and had similar Tl relaxivity rates to other agents already 
being used. Water solubility was a critical factor in the synthesis of our agent 
because when contrast agents are given to patients, they are injected into the 
bloodstream. Blood consists of approximately 92% water, so upon injection, water 
solubility is critical for the agent to effectively enter the bloodstream and affect 
contrast enhancement. 
The synthesis of the desired contrast agent took approximately eight weeks. 
Several steps failed to yield the desired product, so procedures were occasionally 
changed according to the synthesis steps that failed. However, almost everything 
worked according to plan. Some steps took more time than predicted, but still gave 
the desired product. 
Synthesis of cyclenbromoacetate (1 in Figure F) was begun using cyclen 
(1,4, 7,10- tetraazacyclododecane). A stir bar was added to a three-necked 250ml-
round bottom flask. A thermometer, a condenser with a nitrogen inlet, and a funnel 
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were added to the necks of the flask. 5.0 grams of cyclen, 2.6 grams of acetate 
trihydrate, and 20ml of dimethylacetamide were transferred into the flask and the 
mixture was stirred for 30 minutes. Using the addition funnel, 2.82ml of 
bromoacetate in lOmL of dimethylacetamide was added to the stirred mixture drop-
wise over 30 minutes. After complete addition, the mixture was allowed to stir for 60 
hours under nitrogen. 
Cyclenbromoacetate was collected and washed with 10ml of cold 
dimethylacetamide, suctioned dry, washed twice with 25ml of diethyl ether, and 
suctioned dry again. A white, flaky solid resulted and was dissolved in lOOmL of 
dichloromethane. The solution was washed twice with 15ml of water and once with 
15ml of saturated aqueous sodium bromide solution to remove organic materials, 
particularly any acetate anions that were still present. The organic phase was 
collected and passed through a funnel containing magnesium sulfate. The filtrate 
was transferred to a 250ml -round bottom flask and rotavapped to a thin, colorless 
oil. The oil was diluted with 80ml of hexane and stirred for three hours. 
Crystallization began after five minutes of stirring. After stirring, the mixture was 
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cooled using an ice methanol bath and stirred for two more hours. Stirring for two 
hours yielded a white solid, which was collected and washed with cold 
hexane/chloroform (25ml in a 4:1 ratio). The mixture was suctioned dry overnight 
and yielded a small amount of a shapeless, white solid (Moore 2008). Upon 
characterization testing, it was determined that the cyclic product with tertiary butyl 
protecting groups (3 in Figure f) had been successfully synthesized. Product was 







A separate reaction was started to produce a phenyl-piperazine group to be 
added to the protected D03A molecule. The "D03A" in the name represents the 
cyclic part of the ligand that is bound to the gadolinium. To begin, 1.0 grams of 1-
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(2-methoxyphenyl)piperazine, 0.72 grams (472 micro liters) of 3-bromo-1-propanol, 
and 0.72 grams of potassium carbonate were added in 30ml of DMF 
(dimethylformamide) under nitrogen. The mixture was stirred overnight. The next 
day, the reaction was poured onto lOOmL of ice and left open to the atmosphere 
until the ice melted. The aqueous layer was extracted three times using 80ml of 
dichloromethane. The resulting yellow liquid was poured through a funnel 
containing magnesium sulfate into a SOOml-round bottom flask. Rotavapping 






The above product (6) was synthesized by reacting 1.38 grams (0.01 mol) of 
bromoacetic acid (4} with 1.92 grams (0.01 mol) of 1-(2-methoxyphenyl)piperazine 
using DCC. Product 6 was obtained as an off-white solid after recrystallization to be 
a starting material. NMR was run on product 6 to ensure the desired product was 
obtained. From here, 0.14g of product 6 was added to a dry 10ml flask and 0.293g 
of the previously synthesized molecule containing the tertiary butyl protecting 
groups (3) was dissolved in 1ml chloroform and added to the flask. A 
chloroform/methanol Sml mixture was added to the flask (4:1) and the reaction was 
stirred at room temperature for 20 hours under nitrogen. After 20 hours the reaction 
was rotavapped to a tan solid. The solid product was taken up in 3ml of 50% 
dichloromethane/methanol solution. TLC was run in 90% 
dichloromethane/methanol. Both the starting products and the rotavapped product 
were spotted, and the TLC plate showed a spot representing the desired product (7) 
in the middle, as expected (see figure H). The dichloromethane/methanol solution 
purified by column chromatography filled with Silica gel and rotavapped to a tan, 
glassy appearing solid. 
20 
The tan, glassy solid was dissolved in lml trifluoroacetic acid, covered with a 
septum, and stirred for four hours. After stirring, the solution was rotavapped to 
remove the trifluoroacetic acid. 2Sml of chloroform were added and rotavapped off 
to yield the final ligand (8 in Figure 1). The ligand was a golden brown, oily, 
somewhat syrupy liquid. 0.442 grams of product were obtained. Running NMR 




The final synthesis step left was to add the gadolinium to the ligand. Based 
on the amount of ligand obtained, 0.28 grams of ligand was measured and added 
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to 3ml of water. Adding 1M NaOH drop-wise adjusted the pH of the mixture to 6.5. 
Once the pH reached 6.5, a solution of 0.185 grams gadolinium (Ill) chloride and 
2.5ml water was added drop-wise to the ligand. The pH was brought back to 6.5 by 
adding more 1M NaOH drop-wise. The reaction was covered and left to stir 
overnight at pH 6.5. 
A Chelex-100 column was prepared to remove excess gadolinium. To prepare 
the column, 0.5 grams of Chelex-100 was added to a clean beaker. A solution of 1M 
NaOH was added to the Chelex-100. The Chelex-100 mixture was then poured into a 
column and followed by additional 1M NaOH. The 1M NaOH was eluted off the 
column and followed by Milli-Q water until the pH was neutral. 
A clean 50ml flask was placed under the Chelex column. Milli-Q water was 
poured down the column to ensure the pH was still neutral, then the 
ligand/gadolinium mixture was poured through the column. The mixture was eluted 
using Milli-Q water, and the water was rotavapped off. 0.246 grams of crystalline, 
off-white solid Gd-D03A-PP was obtained. The "PP" represents the phenyl-
piperazine functional group. HPLC was performed on Gd-D03A-PP using a Waters 
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NOVA-PAK C18 column with 100% CH3CN as the eluting solvent HPLC indicated 
100% purity of the synthesized agent. 
Figure I 
Tl Relaxation Measurements 
ProHance, Magnevist, and Omniscan were measured, using Tl relaxation times 
to compare their overall relaxation rates to the rate obtained from Gd-D03A-PP. 
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First, a stock solution of O.OOlM was made to use in making five dilutions at 
concentrations of 0.02mM, O.OlmM, 0.025mM, 0.05mM, and O.lmM for each 
contrast agent To make the stock solution, 21..1L of contrast agent was measured and 
added to 9981.JL of 0 20 in a glass vial. The vial was inverted multiple times to ensure 
proper mixing of the solution. The dilutions were made by diluting the stock 
solution and using deuterium oxide (020). To obtain the first dilution at 0.002mM, 
21..1L of stock was mixed with 9981.JL of 020. The second dilution at O.OlmM was 
obtained by adding l01.Jl of stock to 9901.JL of 020. The third dilution at 0.025mM 
was obtained by adding 25lJL of stock to 9751.JL of 020. The fourth dilution at 
O.OSmM was obtained by adding S01..1L of stock to 9501..1L of 0 20. The final dilution at 
O.lOmM was obtained by adding 1001.JL of stock solution to 900 I.JL of 020. HPLC 
vials were used for mixing all solutions and the solutions were transferred to NMR 
tubes. Tl relaxation studies were run on each agent and the individual relaxation 
rates for each concentration were measured and graphed. The slope of the line of 
best fit represented the overall relaxation rate. 
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A stock solution of Gd-D03A-PP was made identically to the other contrast 
agents and used to make five solutions of increasing concentrations (0.02mM, 
O.OlmM, 0.025mM, O.OSmM, and O.lmM) to be tested. The different concentrations 
were tested individually to find the relaxation rates at each specific concentration. 
The data were graphed and the overall relaxivity rate for Gd-D03A-PP was taken 
from the slope of the line of best fit. 
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Results 
Shown below is Figure J obtained from the HPLC purification step. Because 
only one peak is shown at 1.5 minutes, Gd-D03A-PP is deemed to be 100% pure. 
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Figure J 
Nuclear Magnetic Resonance (NMR) Spectroscopy was used to characterize 
the products obtained throughout the entire synthesis of Gd-D03A-PP. The NMR 
seen in Figure K below was run on cyclen (1), one of the starting materials at the 
beginning of the synthesis. The large peak around 2.5-3ppm represents eight CH2 
groups in the ringed structure. The peak around 7.5ppm represents chloroform 
(CHCI3), as the solvent used was deuterated chloroform (CDCI3). 
26 
.. Figure K 
NMR was run on bromoacetamide (6) and results are shown in Figure L 
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NMR was run on the ligand (7) before the tertiary butyl groups were removed and 
results are shown below in Figure M. The large peak around l.Sppm represents the 
tertiary butyl groups that are present. 
I 
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NMR was run on the final ligand (8 in Figure I) without gadolinium added 
and results are shown below. The peaks show the aromatic signals at ~ 7.5ppm 
along with the hydrogens of the cyclen ring ~3-4ppm. The peak at l.Sppm is no 




Table 1 below represents the individual relaxivity rates at each concentration 
of ProHance. Figure N shows the overall relaxivity of ProHance was measured to be 
4.318mM/s. 
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Table 2 represents the individual relaxivity rates at each concentration of 
Magnevist. Figure 0 shows the overall relaxivity was measured to be 5.053mM/s. 
Table 2 
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Figure P 
Table 3 below represents the individual relaxivity rates at each concentration 
of Omniscan. Figure P shows the overall relaxivity was measured to be 4.697mM/s. 
Table 3 
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Figure Q 
Table 4 below represents the individual relaxivity rates at each concentration 
of Gd-D03A-PP. Figure Q shows the overall relaxivity was measured to be 
5.465mM/s. 
Table 4 
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FigureR 
Table 5 represents the relaxivity rates obtained from this research. The first 
column showing the results at l.ST represents the overall relaxivity rates measured in 
this research. The second column represents values found in literature of relaxivity 
rates at 1 T, which is the typica I mag netic field strength of M RI scanners used in 
clinical hospitals. The relaxivity rates are clearly shown to be lower at 1 T, but the 
relaxivity value for Gd-D03A-PP should still be higher than those reported. 
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Table 5 
Contrast Agent Measured Reported Relaxivity Osmolality 
Relaxivity Rate Rate (mM/s) @ 1 T (mOsmol/kg H20) 
(mM/s) @60MHz 
(l.ST) 
ProHance 4.318 3.7 630 
Magnevist 5.054 3.4 1960 
Omniscan 4.698 3.9 798 
Gd-D03A-PP 5.465 - -
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Conclusions and Future Works 
This research was successful in synthesizing a novel, water-soluble gadolinium 
contrast agent with confirmed structure and high purity. The results indicate that, as 
the dilutions of the contrast agent became more concentrated, the Tl values 
decreased. This showed a larger relaxivity rate as the concentrations increased, which 
gave the overall relaxation rate. Gd-D03A-PP obtained the highest relaxation rate of 
5.465mM/s. ProHance acquired the lowest rate of the four compounds at 
4.318mM/s. 
The next step in this research is for our synthesized agent to undergo testing 
to determine the overall relaxivity rate at 1 T. The osmolality of Gd-D03A-PP should 
also be determined. Phantom studies will also be conducted to determine the 
overall contrast enhancement of MRI images. Specificity and uptake in the brain will 
be measured through in vivo imaging in mice or rats. 
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